These findings suggest that therapeutically inhibiting TIGAR functions could sensitize hrHPV-induced cancers to low doses of doxorubicin and may reduce the potential risks for chemotherapy-induced adverse side-effects, such as cardiotoxicity [66,67]. The gene discussed is TIGAR; the disease is cancer.